ENN0403
Phase 2Small molecule
ENN0403 is one of 48 small molecule programs targeting Acute Kidney Injury. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
90 competitors in Acute Kidney Injury
#DrugCompanyPhaseTrials
1Calciparine
BBaxter Healthcare Corporation
Approved
Esbriet
LLegacy Health System
Approved
Viagra
VViatris Specialty LLC
Approved
Ferriprox
CChiesi USA, Inc.
Approved
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Giapreza
LLa Jolla Pharmaceutical Company
Phase 3
Oraverse
LLife Extension Foundation Inc.
Phase 3
Lamisil
NovartisPhase 2
Northera
LundbeckPhase 2
Pitressin
AAultman Health Foundation
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ENN0403. EMBL-EBI & Wellcome Sanger Institute.
- [4]